SLC5A2 and type 1 diabetes mellitus: Recent human studies on the treatment of T1DM with a combination of an SGLT2 inhibitor and insulin have shown that SGLT2 inhibitors assist in controlling the glycaemic levels and reduce the insulin requirements (Evans et al., 2020).